Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide
bioavailability via the L-arginine-nitric oxide pathway, leading to vasodilation and decreased …

Purpose The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of
nebivolol are reviewed. Summary Nebivolol, a third-generation, highly β1-specific β-blocker …

Nebivolol is a third-generation β-adrenoceptor antagonist. It differs from other β-
adrenoceptor antagonists as it combines highly selective β 1-adrenoceptor antagonist …

Introduction: Heart failure (HF) is a common and disabling disease with a high prevalence in
the elderly. Beta-blockers are among the mainstay therapies of HF because they antagonize …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …

Importance of the field: Chronic activation of the sympathetic nervous system leads to
deterioration of cardiovascular function in heart failure patients. In systolic heart failure, β …

Background: Nebivolol is a highly cardioselective long-acting beta-blocker with vasodilating
properties, which acts in part via the endothelial l-arginine/nitric oxide pathway. As an …

Objective: TO describe the pharmacologic and pharmacokinetic properties of a new β-
adrenergic blocker, nebivolol, and review the literature evaluating its efficacy in the …

Nebivolol is a third generation β-blocker. It is highly selective for the β1-adrenoceptor, and
has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a …

Although its clinical use in Europe dates almost 10 years, nebivolol is a β-blocker that has
been only recently introduced in the US market. Like carvedilol, nebivolol belongs to the …